CV Sciences, Inc.
- CVSI · OTC
- Pharmaceutical Preparations
- San Diego, CA
- 44 employees
- CIK 0001510964
Updated from SEC filings through
Top things to know
Executives
- Joseph D. Dowling Chief Executive Officer and Director 10-K, 2026-03-26
- Joerg Grasser Chief Financial Officer 10-K, 2026-03-26
CV Sciences, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in San Diego, CA. It trades as CVSI on OTC. Revenue was $13.8M in the fiscal year ending December 31, 2025, -12.2% from the year before. It reported about 44 employees. Joseph D. Dowling is Chief Executive Officer and Director.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.8M 10-K, 2026-03-26 | $15.7M 10-K, 2026-03-26 | $16.0M 10-K, 2025-03-27 | $16.2M 10-K, 2024-03-29 | $20.0M 10-K, 2022-04-04 |
| Operating income | -$470K 10-K, 2026-03-26 | -$2.2M 10-K, 2026-03-26 | $3.4M 10-K, 2025-03-27 | -$6.8M 10-K, 2024-03-29 | -$18.4M 10-K, 2023-03-30 |
| SG&A | $7.6M 10-K, 2026-03-26 | $9.2M 10-K, 2026-03-26 | $9.7M 10-K, 2025-03-27 | $12.1M 10-K, 2024-03-29 | $25.9M 10-K, 2022-04-04 |
| Net income | -$958K 10-K, 2026-03-26 | -$2.4M 10-K, 2026-03-26 | $3.1M 10-K, 2025-03-27 | -$8.2M 10-K, 2024-03-29 | -$15.6M 10-K, 2023-03-30 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Joseph D. Dowling Chief Executive Officer at CV Sciences, Inc. | Chief Executive Officer and Director | 10-K, 2026-03-26 |
| Joerg Grasser Chief Financial Officer at CV Sciences, Inc. | Chief Financial Officer | 10-K, 2026-03-26 |
What CV Sciences, Inc. does
CV Sciences, Inc. (“CV Sciences,” the “Company,” “we,” “our” or “us”) is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (“B2B”) to business-to-consumer (“B2C”).
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 225.8 million (as of August 11, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $7.0M (as of June 30, 2025) | 10-K, March 26, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
| Latest proxy statement | Meeting April 15, 2026 (filed April 15, 2026) | DEF 14A, April 15, 2026 |
| Auditor | Haskell & White LLP (Irvine, California) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-26
- Item 8.01 Other events
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
- 8-K filed 2026-06-04
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-10
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-03-26
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-10
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2025-11-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-10-10
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2025-09-18
- Item 1.01 Entry into a material definitive agreement
Frequently asked questions about CV Sciences, Inc.
- What does CV Sciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "CV Sciences, Inc. (“CV Sciences,” the “Company,” “we,” “our” or “us”) is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (“B2B”) to business-to-consumer (“B2C”)."
- What is CV Sciences, Inc.'s revenue?
- $13.8M for the fiscal year ending December 31, 2025, from its 10-K filed March 26, 2026.
- Is CV Sciences, Inc. profitable?
- CV Sciences, Inc. reported net income of -$958K for the fiscal year ending December 31, 2025.
- How many employees does CV Sciences, Inc. have?
- About 44 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of CV Sciences, Inc.?
- Joseph D. Dowling, Chief Executive Officer and Director, as named in a 10-K filed March 26, 2026.
- Who is the CFO of CV Sciences, Inc.?
- Joerg Grasser, Chief Financial Officer, as named in a 10-K filed March 26, 2026.
- Where is CV Sciences, Inc. headquartered?
- San Diego, CA.
- What is CV Sciences, Inc.'s stock ticker?
- CVSI on OTC.
- What industry is CV Sciences, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is CV Sciences, Inc.'s website?
- cvsciences.com. Investor relations: https://ir.cvsciences.com.
- When does CV Sciences, Inc. report earnings next?
- November 12, 2026 at 16:30. Source: ir_events.
- Is CV Sciences, Inc. a public company?
- Yes. CV Sciences, Inc. files with the SEC under CIK 0001510964 and trades as CVSI.
- Who audits CV Sciences, Inc.?
- Haskell & White LLP, Irvine, California, as named in its latest annual report (10-K).
- How many shares of CV Sciences, Inc. are outstanding?
- 225.8 million shares as of August 11, 2026, from its 10-Q filed August 13, 2026.
- What is CV Sciences, Inc.'s public float?
- $7.0M as of June 30, 2025, as reported on the cover of its 10-K filed March 26, 2026.
- How many business segments does CV Sciences, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- When is CV Sciences, Inc.'s annual shareholder meeting?
- April 15, 2026, per its proxy statement (DEF 14A) filed April 15, 2026.